STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences, Inc. - GILD STOCK NEWS

Welcome to our dedicated news page for Gilead Sciences (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.

News
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
Rhea-AI Summary
Gilead Sciences' Lead Independent Director, Kevin E. Lofton, has been recognized as one of the most influential leaders in corporate governance by the NACD Directorship 100.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
News
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
Rhea-AI Summary
Gilead Sciences receives positive opinion for use of Veklury in COVID-19 patients with hepatic impairment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
covid-19
-
News
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Rhea-AI Summary
Yescarta achieves a complete metabolic response of 71% at 3 months in patients with relapsed/refractory large B-cell lymphoma, exceeding expectations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
News
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
Rhea-AI Summary
Gilead Sciences announces promising early data from the EVOKE-02 study evaluating Trodelvy in combination with KEYTRUDA in 1L metastatic NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Gilead Prices $2 Billion of Senior Unsecured Notes
Rhea-AI Summary
Gilead Sciences announces pricing of $2 billion senior unsecured notes in a public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
-
News
Gilead Sciences: How One School Has Transformed Education for First-Generation Students
Rhea-AI Summary
Eastside College Preparatory School in East Palo Alto prioritizes accepting low-income and first-generation students, providing free tuition. More than 99% of students go on to college, with the Class of 2023 achieving a 100% college acceptance rate. Gilead Foundation supports the school's efforts to expand and improve.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
News
Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South
Rhea-AI Summary
Gilead Sciences celebrates the fifth anniversary of the COMPASS Initiative, a $100 million commitment to addressing the HIV epidemic in the Southern United States. The program has reached over 300,000 people and trained over 26,000 individuals in leadership development. Gilead plans to expand its support of organizations in the region. The U.S. South accounts for more than 50% of new HIV diagnoses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
News
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Rhea-AI Summary
FDA approves Veklury for use in COVID-19 patients with liver disease, supporting its safety profile. No dose adjustment required. Positive impact on Gilead Sciences (GILD) stock expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
fda approval covid-19
-
News
Gilead Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Gilead Sciences executives to speak at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
News
How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
Rhea-AI Summary
Gilead Sciences' Pharmaceutical Development and Manufacturing (PDM) team plays a key role in creating and delivering medicines. They ensure an adequate and high-quality supply during clinical trials and after product approval. PDM's innovation in manufacturing technology contributes to Gilead's success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
Stock GILD logo
Gilead Sciences, Inc.

Nasdaq:GILD

GILD Rankings

#136 Ranked by Market Cap
#2131 Ranked by Stock Gains
#718 Ranked by Dividends

GILD Stock Data

84.88B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About GILD

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.